Outcome of relapsed/refractory AML patients with IDH1^R132 mutations in real life before the era of IDH1 inhibitors

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors would like to thank the data management unit of CHU Toulouse for its support enabling e-CRF. We thank all the members of the G.A.E.L (Gaël Adolescent Espoir Leucémie) organization and the FONROGA fondation. We are also grateful to Mrs Boubeker for designing the DATAML database logo.

Disclosure statement

C.R has received research grants from Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, Sunesis, Astellas, Daiichi-Sankyo and MaatPharma and is an advisor for Abbvie, Sunesis, Janssen, Jazz Pharmaceuticals, Novartis, Celgene, Astellas, Daiichi-Sankyo, Macrogenics and Pfizer. F.H is an advisor for Amgen, BMS, Celgene, Incyte, Jazz Pharma, Novartis, Pfizer. S.T and E.D are advisors for Novartis. P.B is an advisor for Sanofi and Novartis. S.B is an advisor for Sanofi and Astellas.

Additional information

Funding

This work was supported by the French government under the “Investissement d'avenir” program [ANR-11-PHUC-001].